10815262 ~ GAU: 1633

PTO/SB/08A(04-07)

Modified form approved for use through 09/30/2007. OMB 651-0031
US Patient & Trademark Office: U.S. DEPARTMENT of COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Known Substitute for form 1449A/PTO 10/815,262 **Application Number** March 31, 2004 INFORMATION DISCLOSURE **Filing Date** STATEMENT BY APPLICANT John F. Engelhardt **First Named Inventor** 1633 **Group Art Unit** (Use as many sheets as necessary) Kevin Hill **Examiner Name** Attorney Docket No: 875.074US1

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т1
	"Application Serial No. 09/689,136, Examiner Interview Summary mailed 04-18-05", 3 pgs	
	"Application Serial No. 09/689,136, Examiner Interview Summary mailed 05-16-05", 3 pgs	
	"Application Serial No. 09/689.136. Examiner Interview Summary mailed 09-28-04", 3 pgs	
	"Application Serial No. 10/815,557, Examiner Interview Summary mailed 02-06-07", 4 pgs	
	"Application Serial No. 10/837,029, Examiner Interview Summary mailed 11-15-07", 3 pgs	
	"Application Serial No. 10/837,029, Response filed 11-19-09 to Non-Final Office Action	
	"Application Serial No. 11/301.601. Response filed 01-04-10 to Non-Final Office Action mailed 9-28-09", 12 pgs.	
	"Application Serial No. 11/890,761, Final Office Action mailed 12-22-09", 15 pgs	
	"Application Serial No. 11/890,761, Response filed 04-14-09 to Restriction Requirement mailed 10-14-08", 7 pgs	
	"Application Serial No. 11/890,776, Restriction Requirement mailed 12-17-08", 8 pgs	
	"Australian Application Serial No. 2004227358, Response filed 10-22-09 to Examiner's	
	Second Report dated 08-27-09", 16 pgs.	
	"European Application Serial No. 04749619.5, Communication dated 04-14-08", 5 pgs.	
	"Furopean Application Serial No. 04749619.5, Communication dated 03-11-09", 4 pgs.	ļ
	"European Application Serial No. 04749619.5, Communication dated 09-13-07", 1 pg.	ļ
	"Furopean Application Serial No. 04749619.5, Communication dated 11-09-09", 3 pgs.	<u></u>
	"European Application Serial No. 04749619.5, Communication Noting Loss of Rights dated 11-28-08", 1 pg.	
	"European Application Serial No. 04749619.5, Response filed 02-06-09 to Communication dated 11-28-08", 14 pgs.	
	"European Application Serial No. 04749619.5, Response filed 10-04-07 to Communication dated 09-13-07", 3 pgs.	
	"European Application Serial No. 04749619.5, Response filed 09-21-09 to Office Action mailed 03-11-09", 19 pgs.	
	"International Application Serial No. PCT/US2004/010045, International Search Report mailed 01-10-05", 6 pgs.	
	DENBY, L., et al., "Adeno-associated virus (AAV)-7 and -8 poorly transduce vascular endothelial cells and are sensitive to proteasomal degradation.", Gene Therapy, 12(20), (Oct., 2005), 1534-8	
	JENNINGS, K., et al., "Proteasome Inhibition Enhances AAV-Mediated Transgene Expression in Human Synoviocytes in Vitro and in Vivo", Molecular Therapy, 11(4), (Apr.,	
	2005), 600-607 JOHNSON, J. S., et al., "Enhancement of Adeno-Associated Virus Infection by Mobilizing Capsids into and Out of the Nucleolus", Journal of Virology, 83(6), (2009), 2632-2644	
	KIYOMIYA, K-I, et al., "Proteasome is a Carrier to Translocate Doxorubicin From Cytoplasm into Nucleus", <u>Life Sciences</u> , 62(20), (1998), 1853-1860	

EXAMINER

Sheet 1 of 2

DATE CONSIDERED

10815262 - GAU: 1633

PTO/SB/08A(04-07)

Modified form approved for use through 09/30/2007. OMB 651-0031

US Patent & Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO 10/815,262 **Application Number** March 31, 2004 INFORMATION DISCLOSURE **Filing Date** STATEMENT BY APPLICANT John F. Engelhardt **First Named Inventor** 1633 **Group Art Unit** (Use as many sheets as necessary) Kevin Hill **Examiner Name** Attorney Docket No: 875.074US1 Sheet 2 of 2

OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 1	
·	YAN, Z., et al., "Ubiquitination of Both Adeno-Associated Virus Type 2 and 5 Capsid Proteins Affects the Transduction Efficiency of Recombinant Vectors", <u>Journal of Virology</u> , <u>76(5)</u> , (2002), 2043-2053		